Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosengren, Sanna, Dychter, Samuel S., Printz, Marie A., Huang, Lei, Schiff, Richard I., Schwarz, Hans-Peter, McVey, John K., Drake, Fred H., Maneval, Dan C., Kennard, Don A., Frost, Gregory I., Sugarman, Barry J., Muchmore, Douglas B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540732/
https://www.ncbi.nlm.nih.gov/pubmed/25967925
http://dx.doi.org/10.1208/s12248-015-9782-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540732/
https://www.ncbi.nlm.nih.gov/pubmed/25967925
http://dx.doi.org/10.1208/s12248-015-9782-0

Ejemplares similares